Transfusion-related acute lung injury (TRALI) is defined as a new acute lung injury (ALI) that develops during or within 6 h of transfusion and is a leading cause of transfusion related morbidity and mortality [1] . These causative antibodies in TRALI may be directed against Class I or II human leukocyte antigens (HLA) or human neutrophil antigens (HNA). It may also be caused by lipid products from cellular breakdown, which accumulates in stored blood product and prime and activate neutrophils.
Case Report
A 35 years old female with acute myeloid leukaemia had prolonged neutropenia and thrombocytopenia secondary to chemotherapy induced marrow suppression. The patient was transfused a total of 131 blood components (red cells, platelets and plasma) during the course of hospital stay. Platelet refractoriness was documented after two subsequent platelet transfusions failed to produce acceptable increment. Post transfusion of a 2-day old platelet concentrate from an allogeneic unrelated male donor, the patient developed extreme rigours and chills, fever, tachycardia with deep cyanosis and O 2 saturation of 84% on room air. The patient was intubated and put on mechanical ventilation. Chest X-ray performed after the transfusion event showed bilateral chest infiltrates. TRALI was diagnosed after excluding other causes of ALI.
Results
The Panel reactive antibodies (PRA) of patient revealed HLA Class I and Class II antibodies ( Table 1 ). The implicated donor is a registered voluntary platelet donor with the hospital and his sample was sought immediately after this event for laboratory workup. The donor specific antibody test between recipient and donor pair was positive with a high mean fluorescence intensity (MFI) value for Class I antibodies 10370 and Class II antibodies 3454. The HLA typing of implicated donor is A*02,*03; B*51,*58; DRB1*03,*04. Serum of implicated donor demonstrated HLA Class I antibodies and HLA Class II antibodies ( Table 1) . The donor has a long history of regular donations (25 donations over 7 years) and was not implicated in any transfusion reactions previously. The pre-donation questionnaire and further questioning of donor determined no risk factors for HLA alloimmunization.
Discussion
TRALI can occur in patients undergoing repeated platelet transfusions and has mortality rates between 6 and 20%. Thus, it is important to identify these cases and address the issues related to the patients and implicated donors.
One of the mechanisms of TRALI causation involves a 'two-hit' model. It mentions neutrophil priming as an initial requirement which can be a consequence of hematologic malignancy [2] . transfused product, may lead to activation of the primed and sequestered neutrophils. Even though the ANC was 0.01 9 10 9 /L in our patient, it has been reported by Silliman et al. [3] , that the patients with acute leukaemia undergoing induction chemotherapy, appeared to be at greater risk of developing TRALI. Another hypothesis suggests that transfused HLA antibodies may induce TRALI by direct contact with susceptible endothelial cells of the lung capillaries. It has been postulated that the transfused HLA Class I antibody binds to its cognate antigen present on the pulmonary endothelium. Passively transfused HLA Class II antibodies are known to cause TRALI by activation of monocytes which lead to neutrophil activation [4] .
The mechanism in our patient is a combination of the above factors. The patient has a haematological malignancy with super added enterocolitis which makes her susceptible to TRALI by the two-hit model. The donor derived HLA-A*02 antibodies by binding the pulmonary capillary endothelium may have facilitated the sequestration and activation of neutrophils despite a low ANC. A short duration of the clinical episode may reflect the paucity of entrapped neutrophils. There was also an evidence of HLA Class II antibodies in the implicated donor. Studies have demonstrated that donors serum positive for HLA Class II antibodies, may induce monocytes and possibly platelets [5] to secrete a variety of inflammatory mediators which subsequently activate neutrophils.
We summarize that the laboratory work-up of all cases of TRALI shall be performed to reduce the potential for further cases due to the implicated donor. It is important to perform PRA status of oncology patients at their 1 st hospital visit to enable provision of epitope matched platelet transfusions to prevent development of refractoriness. Baseline PRA of repeat male donors shall be studied to prevent TRALI due to passive transfer of antibodies. Currently, there are no approved national guidelines for laboratory work up of TRALI. However, based on Canadian guidelines we have devised a structured algorithm for work up of such cases at our centre.
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